Update on CAEL-101 from Caelum Biosciences
CAEL-101 UpdateПодробнее
New organ response criteria in amyloidosis diagnosisПодробнее
A Phase 2, Open-Label Study - Safety, Tolerability and Efficacy of Cael-101 in AL Amyloidosis PtsПодробнее
What does the future of amyloidosis treatment look like?Подробнее
CAEL-101 ASH Annual Meeting December 2020 Poster PresentationПодробнее
CAEL-101: a monoclonal antibody therapy for AL amyloidosisПодробнее
CAEL-101 ASH Annual Meeting December 2020 Oral PresentationПодробнее
New organ response criteria for AL amyloidosisПодробнее
An overview of current and future clinical trials in amyloidosisПодробнее
Amyloidosis Forum: Scientific Workshop: Hematological PresentationПодробнее
Results From the CASPIAN Trial in SCLCПодробнее
AC20 - CCF UpdateПодробнее
Developments that are changing the treatment of CLL - current and future drugsПодробнее
The evolution of AL amyloidosis therapyПодробнее
New CLL treatments, the standard of care and the importance of clonal evolutionПодробнее
Dr. Kolberg Explains the Approval Process for BiosimilarsПодробнее
Current and future CLL diagnostic toolsПодробнее
Current and future treatment of SCDПодробнее
